Yibai Tech Unveils Two Flagship Products: 100.MIX Cloud Studio and 100.eHospital Internet Hospital, Driving Digital Transformation in the Pharmaceutical Industry
On the morning of June 15, byVB100, hosted by VCBeat、Yibai Tech Ecosystem CollaborationThe “Digital Marketing for Pharmaceutical Companies” Sub-forum Was Successfully Held.
At this conference,Yibai TechnologyTwo Flagship Products Unveiled at Online Launch Event: “100.eHospital Internet Hospital” and “100.MIX Cloud Director” Officially Debut! It is reported that Yibai Internet Hospital is positioned as a patient-physician integrated platform and a prescription follow-up consultation platform centered on pharmaceutical companies, helping them explore new channels and markets. 100.MIX Cloud Director enables real-time virtual meetings with multiple participants, multi-feeds, and no green screen required across global locations within just ten minutes. By simplifying complex processes, Yibai’s leading technology further elevates industry applications to new heights!
The “Digital Intelligence Ecosystem: Pharmaceutical Digital Marketing 5.0 Summit Forum & 2022 YiBai Tech 100 pMarTech Product Launch” kicked off with an opening address by Ms. Qu Tan, Co-founder and COO of YiBai Tech. The event featured eight industry experts who shared in-depth insights over five hours, sparking lively online discussions.
“From Digital Marketing 1.0 to 5.0, the era of digital-intelligence integration is a long journey. Persisting in doing what is difficult yet right is the responsibility and mission of our generation of pharmaceutical marketing professionals.”
——Qu Tan, Co-founder and COO of Yibai Technology
In her opening remarks, Ms. Qu Tan shared the original mission of Yibai Technology. Over the past five years, Yibai Technology has been committed to empowering marketing through technology and driving data-intelligent marketing with data, providing pharmaceutical companies with comprehensive solutions for “digital academic promotion, digital sales management, and digital doctor-patient management.”, sparing no effort to create more valuable products and services, making healthcare more compassionate.
“Digital Intelligence-Driven Marketing as the Ultimate Goal of Transformation”
——Fang Fen, Senior Researcher at VCBeat Institute
VCBeat Research Institute surveyed nearly ten companies involved in the digital marketing of pharmaceuticals, providing a comprehensive analysis of the industry from perspectives such as industry background, opportunities and challenges in industrial analysis, future trends, and typical case studies, with the aim of offering valuable industry insights to stakeholders.
Core Viewpoints:
A Market Worth Hundreds of Billions, with a Positive Growth Trend.As policies in the pharmaceutical industry continue to tighten, digital marketing strategies have leveraged the pandemic to increase exposure, cultivating physicians’ habits of using digital tools. The traffic dividend is expected to persist, with the market size projected to exceed RMB 100 billion by 2030.
Market Penetration into Lower-Tier Cities, Rising Demand for Online Consultations, and Dual Focus on Online and Offline Services.Primary healthcare demand is substantial, with a clear trend toward market penetration into lower-tier regions; the user base for internet-based healthcare is continuously expanding, highlighting significant demand for online follow-up consultations. The integrated online and offline markets under this new business model will become a critical battleground for pharmaceutical companies’ marketing strategies.
There is an urgent need to improve out-of-hospital medication management for patients with chronic diseases, and digital management and therapy are expected to deepen continuously.For many years, the number of deaths from chronic diseases has ranked first among the total deaths in China, becoming a major issue for Chinese residents.The Leading Killer of Life and Health. Among these, patients with chronic diseases require long-term, regular use of prescription medications; currently, non-adherence to prescribed medication regimens has become one of the primary reasons why chronic disease patients fail to achieve expected treatment outcomes.，Digital management and treatment solutions will continue to be explored in this field.
Technology Empowers Multi-Scenario Pharmaceutical Marketing; Industry Leaders May Emerge in the Next 3–5 Years.PlatformThe service-oriented sector has largely taken shape, with leading companies going public one after another. Retail-end pharmaceutical e-commerce platforms are exerting upward pressure by establishing internet hospitals, and they will continue to enter the front-end marketing market in the future. Technology-enabled service providers that empower pharmaceutical companies with digital marketing solutions across multiple scenarios may see industry leaders emerge within the next three to five years.
“The wave of digitalization has arrived; we hope that industry colleagues will seize the opportunity together to ‘bet big and win big’!”
——Peng Yuanfeng, Head of Omnichannel and Market Access Training, AstraZeneca
Mr. Yuanfeng PengHe first delivered a keynote presentation titled “Marketing Mindset in the Digital Age,” highlighting that the most significant change in the digital era is the spread of word-of-mouth, as well as how to turn brands and products into viral hits and maintain consistent engagement with users.Mr. Peng Yuanfeng proposed the marketing philosophy of “benefiting others and oneself, coexistence and win-win outcomes”: Benefiting others serves as the starting point for our value creation, while benefiting oneself encompasses how value is captured and underscores the need to continuously strengthen one’s core capabilities and competitive advantages. “Coexistence and win-win outcomes” are predicated on addressing a shared problem and pursuing a common goal. By leveraging unique, complementary strengths, this approach ensures that every participant derives long-term benefits, which is essential for success.
“Enterprises must understand and adeptly leverage digital marketing thinking to achieve new growth and create new opportunities for their development.”
——Lin Yanjun, Chief Strategy Officer at MedBai Technology
Mr. Lin YanjunFrom macro to micro perspectives, this report provides a detailed analysis of the pharmaceutical marketing industry, sharing practical case studies and the latest white paper from YiBai Technology. The scale of China’s pharmaceutical marketing market reached RMB 15.4 billion in 2020, with the compound annual growth rate (CAGR) projected to remain at approximately 50%. By 2025, the scale of digital pharmaceutical marketing is expected to exceed RMB 100 billion. In terms of penetration rate, the penetration of pharmaceutical marketing in China was only 2.3% in 2020 and is projected to reach just 11.4% by 2025, significantly lower than the global average. China’s digital transformation in the pharmaceutical sector is currently accelerating to catch up.
The 21st century is an information-driven society, where individuals leave behind various digital footprints online every day. Massive amounts of data, when analyzed and organized across multiple dimensions, become the cornerstone for formulating modern corporate marketing strategies. In today’s society, the application of big data technology plays a pivotal role in enabling us to rapidly acquire actionable information. During the conference,Mr. Lin Yanjun mentioned that Yibai Technology will release the latest edition of the white paper “Insights into HCP Virtual Meeting Behaviors” this June.Stay tuned!
"Market access, patient-centricity, and digitalization will become the core drivers of transformation in pharmaceutical marketing, as well as the competitive moat for pharmaceutical companies."
—— Liu Yong, Vice President of the Marketing Center and Head of Medical & Market Affairs at Haisco Pharmaceutical Group
As an innovative enterprise that took the lead in China to transform and layout digital marketing, Haisco began its strategic deployment of innovative drugs in 2000. In his speech, Mr. Liu Yong highlighted the key factors in the transformation of traditional pharmaceutical companies into innovation-driven enterprises. Mr. Liu Yong believes that from a marketing perspective, shifting policy trends have driven changes in pharmaceutical marketing. Market access, patient-centricity, and digitalization will become the core of these changes and serve as the competitive moat for pharmaceutical companies.
On the topic of how digitalization is applied and implemented in pharmaceutical companies,Mr. Liu YongAn in-depth explanation was also provided: Due to the unique nature of the pharmaceutical industry, its integration with digital marketing progressed slowly during the initial trial phase, then advanced toward a systematic and strategic stage, followed by a new phase of digital intelligence, and ultimately achieved an online-offline closed loop, ushering in the Digital 5.0 era!
“Deep Digital Marketing Is the Future!”
——Feng Rui, Director of the Marketing and Medical Department (concurrently serving as Director of the Big Health Business Planning Department) at Sichuan Otsuka
Mr. Feng RuiDelivered a keynote speech titled “How Digitalization Helps Pharmaceutical Companies Break Through in Marketing Under the New Landscape.” Mr. Feng Rui stated that “deep digital marketing is the future,” outlining an evolution from a “distribution-centric” new digital marketing model, to exploring a hybrid model combining “physician-centric” and “patient-centric” approaches, and ultimately advancing toward a new “patient-centric” digital marketing model driven by both online and offline physician engagement.
“Pharmaceutical companies are integrating their role as builders in the field of digital marketing into the wave of digital development, thereby achieving ecological growth in pharmaceutical marketing.”
——Wang Hui, Autoimmune Market Director at Simcere Pharmaceutical
Ms. Wang HuiOffered unique insights into prescription outflow and out-of-hospital sales practices in the era of digital transformation. Digital operational systems and frameworks that align with the growth trajectory of pharmaceutical companies will serve as a critical foundation for digital marketing. Pharmaceutical enterprises will integrate into the wave of digital development as builders in the field of digital marketing, thereby achieving an ecosystem-driven evolution of their marketing strategies.
The pharmaceutical representative model has suffered severe setbacks, with hospital entry prices for prescription drugs dropping significantly and profit margins further compressed. Ms. Wang Hui analyzed the key factors to consider when building an out-of-hospital system, including five major elements: product characteristics, internal and external organizational structures, high feasibility, clear and well-defined objectives, and favorable policy environments. Additionally, establishing such a system involves three major challenges: shaping patient perceptions, transferring medical resources, and integrating internal organizations.
“Providing pharmaceutical companies with integrated solutions for ‘digital academic promotion, digital sales management, and digital doctor-patient management,’ covering the entire marketing value chain across ‘enterprise–physician–patient–drug.’”
——Qu Tan, Co-founder and COO of Yibai Technology
Finally,Ms. Qu Tanpresented the trend sharing session titled “Integration of Data and Intelligence: 100 pMarTech Solutions Propel Pharmaceutical Digital Marketing into the 5.0 Era,” and provided a detailed introduction toYibai's self-developed 100. pMarTech Technology SaaS Platform, encompassing four major product business matrices: 100. eMarketing Pharmaceutical Digital Marketing Products, 100. CRM+ Intelligent Representative Workbench, 100. eHospital Internet Hospital, and 100. AiData Intelligent Data Platform.Externally, it enables the digitalization of 30+ marketing scenarios; internally, it establishes an integrated marketing management system that spans multiple departments within the enterprise. This helps pharmaceutical companies create a closed-loop digital marketing ecosystem that seamlessly integrates internal and external operations, pioneering a new era of transition from digital operations to integrated management in the pharmaceutical industry.
Yibai Technology, China's leading provider of digital transformation services for pharmaceutical marketing, has served over 1,000 pharmaceutical enterprise clients and more than 100 association clients.
Roundtable Discussion: Digital Intelligence Ecosystem · Pharma Digital Marketing 5.0 Drives Business Breakthrough
The roundtable discussion was moderated byLin Yanjun, Chief Strategy Officer of Yibai TechnologyMr. serves as the host,Mr. Peng Yuanfeng, Head of Omnichannel and Market Access Training at AstraZeneca; Mr. Liu Yong, Vice President of the Marketing Center and Head of Medical and Marketing Departments at Haisco Pharmaceutical Group; Mr. Feng Rui, Director of the Market Medical Department and concurrently Director of the Big Health Business Planning Department at Sichuan Otsuka; Mr. Wang Zheng, General Manager of the Respiratory Therapeutics Division at Hanhui Pharmaceuticals; and Mr. Yang Bin, Deputy General Manager at Paschalin Biopharmaceutical Co., Ltd.Jointly participated in a lively discussion on the topic of digital marketing.
Yibai Technology has been experiencing rapid growth year after year. Throughout the evolution of digital marketing from version 1.0 to the 5.0 era of integrated digital intelligence, Yibai Technology has remained true to its original mission, dedicating itself to the continuous refinement, upgrading, and development of digital marketing in the pharmaceutical industry. Although every participant in this transformation has navigated challenges with caution and perseverance, we firmly believe that a bright future lies ahead. The 5.0 era of pharmaceutical digital marketing is here, and we are ready!